On November 29, 2018 QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported the launch of two novel products to deliver actionable insights on a wide range of blood cancers: a new workflow for the QIAGEN Clinical Insight (QCI) Interpret bioinformatics solution for hematological malignancies, and the new QIAact Myeloid DNA UMI Panel for use in myeloid neoplasm research as a Sample to Insight workflow on QIAGEN’s GeneReader NGS System (Press release, Qiagen, NOV 29, 2018, View Source [SID1234531726]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

QIAGEN is a leader in molecular testing for blood cancers with its ipsogen portfolio of molecular assays, most of which are CE-marked for in vitro diagnostic use. In addition, QIAGEN supplies a very broad portfolio of solutions for research into blood cancers. The company also has a broad intellectual property estate in genes related to blood cancers. These new solutions represent very exciting extensions of this leading blood cancer testing franchise, adding to the complete set of oncology solutions available from QIAGEN.

QIAGEN will highlight these additions to its portfolio at the American Society of Hematology (ASH) (Free ASH Whitepaper) 2018 Annual Meeting and Exposition from December 1-4, 2018, in San Diego. QIAGEN solutions are featured in a number of research studies being presented at ASH (Free ASH Whitepaper) 2018.